Evommune (EVMN) Cash from Investing Activities (2024 - 2026)

Evommune (EVMN) has 3 years of Cash from Investing Activities data on file, last reported at -$85.4 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 732.29% year-over-year to -$85.4 million in Q1 2026; TTM through Mar 2026 was -$227.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$115.3 million, down 2787.73% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$85.4 million, up from -$122.9 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for EVMN reached as high as $13.5 million in Q1 2025 and fell as low as -$122.9 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$57.0 million across 3 years, with a median of -$59.2 million in 2024.
• Across the five-year window, Cash from Investing Activities plunged 271.53% in 2025 and sank 732.29% in 2026, its largest moves.
• Year by year, Cash from Investing Activities stood at -$33.1 million in 2024, then plunged by 271.53% to -$122.9 million in 2025, then surged by 30.55% to -$85.4 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$85.4 million in Q1 2026, -$122.9 million in Q4 2025, and $13.5 million in Q1 2025.